Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 854

Sort by

Sort Order Select

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

No Increased Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

Margaux Lafaurie, PharmD, Bérangère Baricault, Vincent Soler, MD PhD, Myriam Cassagne, MD PhD, Laurent Sailler, MD PhD, Maryse Lapeyre-Mestre, MD PhD, Agnès Sommet, MD PhD, Guillaume Moulis, MD PhD

Blood (2019) 134 (Supplement_1): 2363.

https://doi.org/10.1182/blood-2019-124729

Published: 2019

Journal Articles

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Blood (2019) 134 (Supplement_1): 2426.

https://doi.org/10.1182/blood-2019-129820

Published: 2019

Journal Articles

Natural History of Tumor Thrombus: A Single-Centre Retrospective Study

Curtis Marcoux, MD MSc, Shahad Al Ghamdi, MD, Daria Manos, MD, Mary-Margaret Keating, MD, Sudeep P Shivakumar, MD BSc

Blood (2019) 134 (Supplement_1): 2430.

https://doi.org/10.1182/blood-2019-124476

Published: 2019

Journal Articles

Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress

Kevin H. M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB BS, Katrin Uhlig, MD MS, Megan Lynch, MSN, NP, Li Liu, PhD, Elliott P. Vichinsky, MD

Blood (2019) 134 (Supplement_1): 2249.

https://doi.org/10.1182/blood-2019-123113

Published: 2019

Journal Articles

Approaching Venous Thromboembolism Disease (DVT) from Another Perspective: Better Management in a Multidisciplinary DVT Unit Improves Clinical Outcomes and Post Thrombotic Syndrome. One-Year Experience in Our Hospital

Milagros Suito, MD, Maria Cerdá, MD, Olga Benítez, MD, Alba Cabirta, MD, Francesc Bosch, MD PhD, Amparo Santamaria, MD PhD

Blood (2019) 134 (Supplement_1): 2431.

https://doi.org/10.1182/blood-2019-131327

Published: 2019

Journal Articles

Alternative Splicing and Intronic Polyadenylation Post-Transcriptionally Regulate CSF3R Via a Cryptic Exon

Lawrence J Druhan, PhD, Amanda Lance, MS, Alicia Hamilton, Nury M Steuerwald, PhD, Elise Tjaden, Belinda R Avalos, MD

Blood (2019) 134 (Supplement_1): 2462.

https://doi.org/10.1182/blood-2019-129102

Published: 2019

Journal Articles

Three-D Models for Megakaryopoiesis and Platelet Production

Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): SCI-36.

https://doi.org/10.1182/blood-2019-121076

Published: 2019

Journal Articles

The Detection of Minor Clones with Somatic KIT D816V Mutations Using Droplet Digital PCR in Pediatric De Novo AML: AML-05 Trial from the Japanese Pediatric Leukemia/Lymphoma Study Group

Blood (2019) 134 (Supplement_1): 1419.

https://doi.org/10.1182/blood-2019-127656

Published: 2019

Journal Articles

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris Afanasyev, MD PhD, Sebastian Grosicki, MD PhD, Maria Socorro O Portella, MD MBA, Zewen Zhu, Dominik Selleslag, MD

Blood (2019) 134 (Supplement_1): 3740.

https://doi.org/10.1182/blood-2019-130309

Published: 2019

Journal Articles

Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients

Alexandre Sostelly, M.Eng., PhD, Simon Buatois, Antoine Soubret, Erica Winter, PharmD, Barbara Klughammer, PhD, Joy C. Hsu, Gregor Jordan, Christoph Bucher, MD, Jean-Eric Charoin, Keisuke Gotanda, Kenji Shinomiya, Zsolt Nagy, MD PhD, Jens P. Panse, Sung-Soo Yoon, MD PhD, Régis Peffault de Latour, MD PhD, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD

Blood (2019) 134 (Supplement_1): 3745.

https://doi.org/10.1182/blood-2019-124258

Published: 2019

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Ivan Sloma, PharmD, PhD, Philip Beer, PhD FRCPath, MRCP, Christophe Desterke, PhD, Elizabeth Bulaeva, Misha Bilenky, Michelle Moksa, Kamini Raghuram, Cedric Brimacombe, Karen Lambie, Ali G Turhan, MD PhD, Orianne Wagner-Ballon, MD PhD, Philippe Gaulard, MD PhD, R. Keith Humphries, MD PhD, Martin Hirst, PhD BS, Connie J. Eaves, PhD

Blood (2019) 134 (Supplement_1): 4139.

https://doi.org/10.1182/blood-2019-127839

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Caspar Da Cunha-Bang, MD PhD, Rudy Agius, Arnon P. Kater, Mark-David Levin, MD PhD, Anders Österborg, MD PhD, Mattias Mattsson, MD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4304.

https://doi.org/10.1182/blood-2019-121907

Published: 2019

Journal Articles

Binding of Factor VIII to D'D3 and A2 Domains of Von Willebrand Factor Facilitates Mechanical Unraveling of the A2 Domain

Wenjing Cao, MD,PhD, Wenpeng Cao, Wei Zhang, X. Long Zheng, MD, PhD, Xiaohui (Frank) Zhang, PhD

Blood (2019) 134 (Supplement_1): 95.

https://doi.org/10.1182/blood-2019-125115

Published: 2019

Journal Articles

Benefit and Safety of Isovolemic Hemodilution Prior to Red Cell Exchange in Chronically Transfused Sickle Cell Patients

Katayoun Fomani, MD, Cindy Xu, Swathi Ratkal, MD, Vijay Nandi, PhD, Abena Appiah-Kubi, MD MPH, Banu Aygun, MD, James Louie, MD, Patricia Shi, MD

Blood (2019) 134 (Supplement_1): 2291.

https://doi.org/10.1182/blood-2019-122259

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Mutational landscape of gray zone lymphoma

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

No Increased Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Natural History of Tumor Thrombus: A Single-Centre Retrospective Study

Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress

Approaching Venous Thromboembolism Disease (DVT) from Another Perspective: Better Management in a Multidisciplinary DVT Unit Improves Clinical Outcomes and Post Thrombotic Syndrome. One-Year Experience in Our Hospital

Alternative Splicing and Intronic Polyadenylation Post-Transcriptionally Regulate CSF3R Via a Cryptic Exon

Three-D Models for Megakaryopoiesis and Platelet Production

The Detection of Minor Clones with Somatic KIT D816V Mutations Using Droplet Digital PCR in Pediatric De Novo AML: AML-05 Trial from the Japanese Pediatric Leukemia/Lymphoma Study Group

Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Binding of Factor VIII to D'D3 and A2 Domains of Von Willebrand Factor Facilitates Mechanical Unraveling of the A2 Domain

Benefit and Safety of Isovolemic Hemodilution Prior to Red Cell Exchange in Chronically Transfused Sickle Cell Patients

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only